Advanced search
1 file | 1.27 MB Add to list

Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer

(2021) RADIOTHERAPY AND ONCOLOGY. 155. p.160-166
Author
Organization
Abstract
Objective: The PORTEC-4a trial investigates molecular-integrated risk profile guided adjuvant treatment for endometrial cancer. The quality assurance programme included a dummy run for vaginal brachytherapy prior to site activation, and annual quality assurance to verify protocol adherence. Aims of this study were to evaluate vaginal brachytherapy quality and protocol adherence. Methods: For the dummy run, institutes were invited to create a brachytherapy plan on a provided CT-scan with the applicator in situ. For annual quality assurance, institutes provided data of one randomly selected brachytherapy case. A brachytherapy panel reviewed and scored the brachytherapy plans according to a checklist. Results: At the dummy run, 15 out of 21 (71.4%) institutes needed adjustments of delineation or planning. After adjustments, the mean dose at the vaginal apex (protocol: 100%; 7 Gy) decreased from 100.7% to 99.9% and range and standard deviation (SD) narrowed from 83.6-135.1 to 96.4-101.4 and 8.8 to 1.1, respectively. At annual quality assurance, 22 out of 27 (81.5%) cases had no or minor and 5 out of 27 (18.5%) major deviations. Most deviations were related to delineation, mean dose at the vaginal apex (98.0%, 74.7-114.2, SD 7.6) or reference volume length. Conclusions: Most feedback during the brachytherapy quality assurance procedure of the PORTEC-4a trial was related to delineation, dose at the vaginal apex and the reference volume length. Annual quality assurance is essential to promote protocol compliance, ensuring high quality vaginal brachytherapy in all participating institutes. (C) 2020 The Authors. Published by Elsevier B.V.
Keywords
Oncology, Radiology Nuclear Medicine and imaging, Hematology, Endometrial cancer, Brachytherapy, Quality assurance, Dummy run

Downloads

  • PORTEC4a QA.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 1.27 MB

Citation

Please use this url to cite or link to this publication:

MLA
Wortman, B. G., et al. “Brachytherapy Quality Assurance in the PORTEC-4a Trial for Molecular-Integrated Risk Profile Guided Adjuvant Treatment of Endometrial Cancer.” RADIOTHERAPY AND ONCOLOGY, vol. 155, 2021, pp. 160–66, doi:10.1016/j.radonc.2020.10.038.
APA
Wortman, B. G., Astreinidou, E., Laman, M. S., van der Steen-Banasik, E. M., Lutgens, L. C. H. W., Westerveld, H., … Nout, R. A. (2021). Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer. RADIOTHERAPY AND ONCOLOGY, 155, 160–166. https://doi.org/10.1016/j.radonc.2020.10.038
Chicago author-date
Wortman, B.G., E. Astreinidou, M.S. Laman, E.M. van der Steen-Banasik, L.C.H.W. Lutgens, H. Westerveld, F. Koppe, et al. 2021. “Brachytherapy Quality Assurance in the PORTEC-4a Trial for Molecular-Integrated Risk Profile Guided Adjuvant Treatment of Endometrial Cancer.” RADIOTHERAPY AND ONCOLOGY 155: 160–66. https://doi.org/10.1016/j.radonc.2020.10.038.
Chicago author-date (all authors)
Wortman, B.G., E. Astreinidou, M.S. Laman, E.M. van der Steen-Banasik, L.C.H.W. Lutgens, H. Westerveld, F. Koppe, A. Slot, H.A. van den Berg, M.E. Nowee, S. Bijmolt, T.C. Stam, A.G. Zwanenburg, J.W.M. Mens, I.M. Jürgenliemk-Schulz, A. Snyers, C.M. Gillham, N. Weidner, S. Kommoss, Katrien Vandecasteele, V. Tomancova, C.L. Creutzberg, and R.A. Nout. 2021. “Brachytherapy Quality Assurance in the PORTEC-4a Trial for Molecular-Integrated Risk Profile Guided Adjuvant Treatment of Endometrial Cancer.” RADIOTHERAPY AND ONCOLOGY 155: 160–166. doi:10.1016/j.radonc.2020.10.038.
Vancouver
1.
Wortman BG, Astreinidou E, Laman MS, van der Steen-Banasik EM, Lutgens LCHW, Westerveld H, et al. Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer. RADIOTHERAPY AND ONCOLOGY. 2021;155:160–6.
IEEE
[1]
B. G. Wortman et al., “Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer,” RADIOTHERAPY AND ONCOLOGY, vol. 155, pp. 160–166, 2021.
@article{8699486,
  abstract     = {{Objective: The PORTEC-4a trial investigates molecular-integrated risk profile guided adjuvant treatment for endometrial cancer. The quality assurance programme included a dummy run for vaginal brachytherapy prior to site activation, and annual quality assurance to verify protocol adherence. Aims of this study were to evaluate vaginal brachytherapy quality and protocol adherence.

Methods: For the dummy run, institutes were invited to create a brachytherapy plan on a provided CT-scan with the applicator in situ. For annual quality assurance, institutes provided data of one randomly selected brachytherapy case. A brachytherapy panel reviewed and scored the brachytherapy plans according to a checklist.

Results: At the dummy run, 15 out of 21 (71.4%) institutes needed adjustments of delineation or planning. After adjustments, the mean dose at the vaginal apex (protocol: 100%; 7 Gy) decreased from 100.7% to 99.9% and range and standard deviation (SD) narrowed from 83.6-135.1 to 96.4-101.4 and 8.8 to 1.1, respectively. At annual quality assurance, 22 out of 27 (81.5%) cases had no or minor and 5 out of 27 (18.5%) major deviations. Most deviations were related to delineation, mean dose at the vaginal apex (98.0%, 74.7-114.2, SD 7.6) or reference volume length.

Conclusions: Most feedback during the brachytherapy quality assurance procedure of the PORTEC-4a trial was related to delineation, dose at the vaginal apex and the reference volume length. Annual quality assurance is essential to promote protocol compliance, ensuring high quality vaginal brachytherapy in all participating institutes. (C) 2020 The Authors. Published by Elsevier B.V.}},
  author       = {{Wortman, B.G. and Astreinidou, E. and Laman, M.S. and van der Steen-Banasik, E.M. and Lutgens, L.C.H.W. and Westerveld, H. and Koppe, F. and Slot, A. and van den Berg, H.A. and Nowee, M.E. and Bijmolt, S. and Stam, T.C. and Zwanenburg, A.G. and Mens, J.W.M. and Jürgenliemk-Schulz, I.M. and Snyers, A. and Gillham, C.M. and Weidner, N. and Kommoss, S. and Vandecasteele, Katrien and Tomancova, V. and Creutzberg, C.L. and Nout, R.A.}},
  issn         = {{0167-8140}},
  journal      = {{RADIOTHERAPY AND ONCOLOGY}},
  keywords     = {{Oncology,Radiology Nuclear Medicine and imaging,Hematology,Endometrial cancer,Brachytherapy,Quality assurance,Dummy run}},
  language     = {{eng}},
  pages        = {{160--166}},
  title        = {{Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer}},
  url          = {{http://dx.doi.org/10.1016/j.radonc.2020.10.038}},
  volume       = {{155}},
  year         = {{2021}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: